"You’d think companies would want their products’ names to be memorable, catchy and descriptive: Windex, Duracell, KitchenAid ...

Alongside the data in PsA, UCB will present at EULAR new results demonstrating that Bimzelx delivered sustained clinical ...

Belgian drugmaker UCB (Euronext: UCB) today announced new three-year data from Phase III trials, and their open-label ...

UCB has announced new three-year data from phase 3 trials and their open-label extensions investigating BIMZELX (bimekizumab) ...

MoonLake Immunotherapeutics shares surged 31% after the Financial Times reported, citing unnamed sources, that the company had rejected an initial acquisition offer by Merck & Co. for more than $3 ...

Biotech stock MoonLake Immunotherapeutics rocketed Tuesday on a report Merck offered to buy it for "more than $3 billion." ...

Just over six months into its dual launch across Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA), UCB’s Bimzelx (bimekizumab) is demonstrating meaningful ...

On May 27, analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) while keeping the price target at $45. The reiterated bullish sentiment comes ...

DTs are painful, pus-discharging tunnels under the skin resulting from long-term inflammation, frequently leading to scarring Clinically meaningful relief from skin pain: At two years of BIMZELX ...

Brussels (Belgium), March 7, 2025 – 14:00 (CET) – UCB, a global biopharmaceutical company, today announced two-year data from the BE HEARD^ trials for BIMZELX ® (bimekizumab-bkzx) in moderate to ...